Abstract 5344
Background
Recent data on world-wide trends in population-based survival from glioblastoma are not available. We aimed to investigate disparities in survival using data contributed to the third cycle of the CONCORD programme (CONCORD-3).
Methods
Age-specific and age-standardised net survival was estimated using the non-parametric Pohar Perme estimator, correcting for background mortality by single year of age, sex and calendar year in each country.
Results
During 2000-2004, age-standardised two-year net survival was mostly in the range 10-20%, but survival was less than 10% in Finland, Lithuania, the Netherlands, and New Zealand. Survival between 2005 and 2009 was slightly higher, in the range 20-30% in several countries, while it remained around 10-20% in Finland, Poland, the Russian Federation, Spain, Thailand, and the United Kingdom. During 2010-2014, age-standardised two-year survival was still below 20% in Poland, the Russian Federation, Spain, Thailand, and the United Kingdom. It reached 30% in Japan, Korea and Singapore, and survival otherwise stabilised in the range 20-30%. In patients younger than 45 years, age-standardised two-year net survival during 2000-2004 was 30% or less in 15 countries, including Canada, France, Ireland, Israel, New Zealand, Norway, Portugal, Slovakia and Switzerland, while it was in the range 35-40% in Belgium, Italy, Japan, Korea and the United States. During 2005-2009, 14 countries still lagged behind, with two-year net survival below 35% (e.g. Canada, France, Ireland, Portugal, the Russian Federation, Slovakia, Sweden), while survival rose to 45% or more in Australia, Belgium, Japan, Korea, Slovenia and Switzerland. More recently (2010-2014), two-year net survival was still 35% or less in France, Ireland, Portugal, the Russian Federation and Slovakia.
Conclusions
The increase in population-based survival from glioblastoma during 2000-2014 is likely to have been determined by the use of chemo-radiation in eligible patients from 2005 onwards. However, there were wide international disparities, suggesting little or no uptake of chemo-radiation protocols, especially in younger patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
London School of Hygiene and Tropical Medicine.
Funding
Davidson and O’Gorman Fellowship from Children with Cancer UK.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757 - Development of chimeric antigenic receptor (CAR) against VEGFR2 for solid tumor treatment
Presenter: Li-Shuang Ai
Session: Poster Display session 1
Resources:
Abstract
4156 - Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells.
Presenter: Nunzia Matrone
Session: Poster Display session 1
Resources:
Abstract
2949 - EGFR-mediated PD-L1 upregulation in HER2+ breast cancer (BC) cell line models
Presenter: Nicola Gaynor
Session: Poster Display session 1
Resources:
Abstract
4270 - The impact of cortisol on immune cells and its effect on cancer-immune cells co-culture in a 3D spheroid of ovarian cancer
Presenter: Maysa Al-natsheh
Session: Poster Display session 1
Resources:
Abstract
1568 - Application of sonoporation to increase anticancer drug efficacy in 2D and 3D NSCLC cell cultures
Presenter: Vilma Petrikaite
Session: Poster Display session 1
Resources:
Abstract
5400 - Tr1-like cells in human peripheral blood are part of the T effector memory pool and are preferentially stimulated via CD55
Presenter: Iniobong Charles
Session: Poster Display session 1
Resources:
Abstract
5817 - Functional analysis of tumor infiltrating lymphocytes in triple negative breast cancer focusing on granzyme B
Presenter: Hitomi Kawaji
Session: Poster Display session 1
Resources:
Abstract
2287 - Aberrant glycolysis associates with inflammatory tumor microenvironment and promotes metastasis in triple-negative breast cancer
Presenter: Chengwei Lin
Session: Poster Display session 1
Resources:
Abstract
735 - Anti-cancer effects of differentiation-inducing factor-1 in triple negative breast cancer.
Presenter: Fumi Tetsuo
Session: Poster Display session 1
Resources:
Abstract
2105 - The Inhibitory Effect in Oral Squamous Cell Carcinoma Cells by Knocking down Matrix Metalloproteinase 9
Presenter: Xinyan Zhang
Session: Poster Display session 1
Resources:
Abstract